These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25931315)

  • 1. Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
    Yossi S; Linot B; Peyraga G; Breheret R; Laccourreye L; Capitain O
    Int J Clin Oncol; 2015 Dec; 20(6):1086-92. PubMed ID: 25931315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
    Lin JT; Lai GM; Chang TH; Liu MT; Bi CP; Wang JW; Chen MK
    Adv Ther; 2012 Jan; 29(1):71-7. PubMed ID: 22161550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
    Watanabe A; Taniguchi M; Sasaki S
    Anticancer Drugs; 2003 Nov; 14(10):801-7. PubMed ID: 14597874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
    Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
    BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
    Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
    Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
    Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
    Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
    Billan S; Kaidar-Person O; Atrash F; Doweck I; Haim N; Kuten A; Ronen O
    Isr Med Assoc J; 2013 May; 15(5):231-5. PubMed ID: 23841243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
    Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P
    Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
    Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
    Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
    Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
    Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
    Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
    Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.